e-learning
resources
Berlin 2001
Sunday 23.09.2001
Inflammation, infection and exercise capacity in cystic fibrosis patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The epidemiology and invasive therapy of portal hypertension in cystic fibrosis
O. Efrati, A. Barak, Y. Bujanover, Y. Yahav (Ramat Gan, Israel)
Source:
Annual Congress 2001 - Inflammation, infection and exercise capacity in cystic fibrosis patients
Session:
Inflammation, infection and exercise capacity in cystic fibrosis patients
Session type:
Thematic Poster Session
Number:
865
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Efrati, A. Barak, Y. Bujanover, Y. Yahav (Ramat Gan, Israel). The epidemiology and invasive therapy of portal hypertension in cystic fibrosis. Eur Respir J 2001; 16: Suppl. 31, 865
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Related content which might interest you:
Pulmonary arterial hypertension and advanced lung disease in cystic fibrosis patients
Source: Eur Respir J 2007; 30: Suppl. 51, 387s
Year: 2007
Pulmonary hypertension in cystic fibrosis patients
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008
Prevalence, risk factors and prognosis of pulmonary hypertension in cystic fibrosis
Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge
Year: 2011
Electrocardiographical characteristics of pulmonary arterial hypertension in children with cystic fibrosis
Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies
Year: 2010
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Pulmonary hypertension as a predictor of survival in cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 230s
Year: 2003
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Source: Eur Respir J 2007; 30: 715-721
Year: 2007
Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005
Comparison of clinical characteristics and prognostic factors between combined pulmonary fibrosis and emphysema/UIP versus non-UIP
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Update on management of lung infection in cystic fibrosis
Source: Virtual Congress 2020 – Updates in cystic fibrosis
Year: 2020
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir Mon 2012; 57: 148-160
Year: 2012
Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Antibiotic treatment of cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 188-202
Year: 2014
Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease
Source: Eur Respir J 2012; 39: 125-132
Year: 2012
Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease
Source: Eur Respir J 2011; 39: 125-132
Year: 2012
Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
Source: ERJ Open Res, 4 (1) 00111-2017; 10.1183/23120541.00111-2017
Year: 2018
Pathophysiology of cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 1-13
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept